• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference

    12/16/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email

    Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time).

    The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events.

    About Insulet Corporation:

    Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.

    ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251216562336/en/

    Investor Relations:

    Clare Trachtman

    Vice President, Investor Relations

    (978) 218-0889

    [email protected]

    Media:

    Angela Geryak Wiczek

    Senior Director, Corporate Communications

    (978) 932-0611

    [email protected]

    Get the next $PODD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    12/16/2025$370.00Outperform
    Evercore ISI
    11/19/2025$400.00Neutral → Buy
    UBS
    10/21/2025$370.00Buy
    Stifel
    9/8/2025$365.00Outperform
    Oppenheimer
    6/16/2025$365.00Buy
    Truist
    5/30/2025$380.00Buy
    Goldman
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $PODD
    SEC Filings

    View All

    Insulet Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    12/17/25 4:02:58 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Insulet Corporation

    10-Q - INSULET CORP (0001145197) (Filer)

    11/6/25 4:25:43 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    11/6/25 7:11:38 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Frederick Wayne A.I. sold $542,510 worth of shares (1,851 units at $293.09), decreasing direct ownership by 46% to 2,158 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    12/16/25 4:04:04 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Stonesifer Timothy C. bought $299,884 worth of shares (962 units at $311.73), increasing direct ownership by 27% to 4,591 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    12/8/25 4:02:55 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Huffines Robert Luther was granted 477 shares (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    11/3/25 5:36:15 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference

    Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omni

    12/16/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future

    Expansion follows successful multi-year pilots in Massachusetts and California, and longstanding Pod takeback programs in Europe, Canada, and Australia Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers. "Here at Insulet, our mission is to transform the lives of people with diabetes, and we are equally committed to creating a more sustainable future," said Carolyn Sleeth, Senior Vice President and U.S. General Manager. "We are proud of the success achieved through our Massachusetts

    12/15/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

    New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested new features enable healthcare providers to more effectively modify diabetes therapy to meet needs of people with diabetes. Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in tubeless diabetes tec

    12/4/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Insulet with a new price target

    Evercore ISI initiated coverage of Insulet with a rating of Outperform and set a new price target of $370.00

    12/16/25 9:28:48 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet upgraded by UBS with a new price target

    UBS upgraded Insulet from Neutral to Buy and set a new price target of $400.00

    11/19/25 8:31:06 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Insulet with a new price target

    Stifel resumed coverage of Insulet with a rating of Buy and set a new price target of $370.00

    10/21/25 7:21:42 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stonesifer Timothy C. bought $299,884 worth of shares (962 units at $311.73), increasing direct ownership by 27% to 4,591 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    12/8/25 4:02:55 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    8/29/24 4:17:26 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

    4 - INSULET CORP (0001145197) (Issuer)

    9/21/23 4:48:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f

    10/23/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Host Investor Day on November 20, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's Acton, Massachusetts headquarters on Thursday, November 20, 2025. The Investor Day will include presentations from the management team highlighting the Company's longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET). The Company invites in

    10/10/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Announces CFO Transition

    Flavia Pease Appointed Chief Financial Officer Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. "I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth," said Ashley McEvoy, Insulet President and Chief Executive Officer. "She has been instrumental in strengthening our financial

    9/16/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Financials

    Live finance-specific insights

    View All

    Insulet Reports Third Quarter 2025 Results

    Raises Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025. Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant currency1, and exceeded the high end of the Company's guidance range of 22% - 25% at constant currency rates Total Omnipod revenue of $699.2 million, rose 31.0%, or 29.3% in constant currency U.S. Omnipod revenue of $497.1 million, grew 25.6% International Omnipod revenue of $202.1 million, advanced 46.5%,

    11/6/25 6:30:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)

    Raising Full Year Revenue and Adjusted Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in cons

    8/7/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2

    7/8/25 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    10/7/24 11:37:08 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    2/13/24 5:06:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care